Market capitalization | $1.80b |
Enterprise Value | $1.36b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 52.14 |
EV/Sales (TTM) EV/Sales | 4.07 |
P/S ratio (TTM) P/S ratio | 5.41 |
P/B ratio (TTM) P/B ratio | 9.43 |
Revenue growth (TTM) Revenue growth | -22.97% |
Revenue (TTM) Revenue | $333.58m |
As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.
18 Analysts have issued a Immunocore Holdings plc - ADR forecast:
18 Analysts have issued a Immunocore Holdings plc - ADR forecast:
Mar '25 |
+/-
%
|
||
Revenue | 334 334 |
23%
23%
|
|
Gross Profit | 330 330 |
23%
23%
|
|
EBITDA | -44 -44 |
56%
56%
|
EBIT (Operating Income) EBIT | -48 -48 |
54%
54%
|
Net Profit | -22 -22 |
76%
76%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Head office | United Kingdom |
CEO | Bahija Jallal |
Employees | 493 |
Founded | 2021 |
Website | www.immunocore.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.